Talis Biomedical Corp
DelistedCIK 1584751fmd_1V7PTG8CGFF1PDD25ECEMKN47SManufacturing · Laboratory Analytical InstrumentsTemplate: Standard
Coverage: Jan 01, 2020 to Jun 30, 2024, 18 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|
| Total revenues | – | 8 | 5 | 2 |
| Cost of revenue | – | 0 | 8 | 0 |
| Gross profit | – | 8 | (4) | 2 |
| Research and development | 89 | 158 | 71 | 41 |
| Selling, general and administrative | 13 | 42 | 41 | 28 |
| Total operating expenses | 102 | 200 | – | – |
| Operating income | (91) | (192) | (115) | (67) |
| Other non-operating income (expense) | 0 | (0) | 2 | 5 |
| Income tax expense | 0 | 0 | 0 | 0 |
| Net income | (91) | (192) | (113) | (62) |